Peanut Allergy Treatment Market Size & Share 2024 - 2032

Peanut Allergy Treatment Market Size

Peanut Allergy Treatment Market size was valued at USD 483.5 million in 2023 and is anticipated to showcase growth at 12.1% CAGR from 2024 to 2032. Growing prevalence of peanut allergies, increasing approvals for immunotherapeutic treatments, and increasing investments for developing new treatment modalities is driving the revenue growth of the global market. Additionally, rising awareness towards timely treatment of peanut allergies is also adding to the revenue growth of the market.

Peanut allergy treatment includes various therapeutic interventions designed to manage and treat allergies. This market includes a range of treatment modalities aimed at reducing allergic reactions and increase tolerance to peanut proteins to improve the quality of life of patients.
 

Peanut Allergy Treatment Market Trends

• Epicutaneous immunotherapy is an emerging treatment option for peanut allergies, specifically among pediatric patients. Products such as Viaskin peanut patch has shown promising potential in desensitizing many peanut-allergic pediatric patients. This desensitization helps in lowering the risk of allergic reactions from accidental exposure to peanut. Vendors are increasingly exploring potentials of epicutaneous immunotherapy which is expected to offer lucrative growth opportunities during the forecast period.
   
• Moreover, increasing investments by vendors have resulted in the existence of robust pipeline of potential candidates of immunotherapy drugs such as ADP101, PVX108, VE416, INP20. Owing to their high potential of success, these products are securing significant investments for clinical developments. For instance, in December 2022, Aravax Pty Ltd initiated its series B funding round, through securing an investment of ~USD 22 million to commence phase II clinical trials for PVX108, a promising candidate for treating peanut allergies.
   

Peanut Allergy Treatment Market Analysis

Based on route of administration, the market is segmented into injectable, oral, and other routes of administration. The injectable segment held the majority of market share in 2023 of about 51.4%.
 

• Injections find extensive use in delivering epinephrine and immunotherapeutic treatments such as Dupixent (Regeneron Pharmaceuticals and Sanofi). Immunotherapeutic treatments target specific pathways in the immune system and require their delivery directly into the bloodstream, ensuring rapid and specific action. As a result, the adoption of injection as a preferred route of administration has increased globally.
   
• Injections are often administered at intervals (weekly/monthly), which makes them more convenient for patients and increases patient compliance compared to oral therapies. Furthermore, injectable biologics are used for treating multiple autoimmune allergic conditions that makes injections a preferred option for patients with multiple allergies.
   

Based on drug class, the peanut allergy treatment market is classified into epinephrine, antihistamines, immunotherapies, and other drug classes. The epinephrine segment dominated the market with a revenue of about USD 233 million in 2023.
 

• Growing use of epinephrine injections as an emergency injection (first-line treatment) for treating severe peanut allergies is driving the revenue growth of the segment. Epinephrine helps to reverse any life-threatening symptoms such as swelling of the airway and low blood pressure and thus is commonly prescribed for use during life threatening situations.
   
• Additionally, epinephrine injections are among the commonly prescribed injections for other food allergies, which has eased their availability across pharmacies, increasing their adoption among allergic patients globally. Furthermore, many patients with peanut allergies carry epinephrine autoinjectors, that are easy to use and can be self-administered.

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channels, the peanut allergy treatment market is classified into hospital pharmacies, retail pharmacies, and other distribution channels. The hospital pharmacies segment dominated the market with a revenue of about USD 267.8 million in 2023.
 

• The dominating share of the hospital pharmacies can be attributed to an easy availability of specialized treatments such as oral immunotherapeutic drugs across them due to their specialized nature and the need for close monitoring during initial doses.
   
• Moreover, hospital pharmacies often have the capability to offer compounded medications, including customized formulation of immunotherapy for peanut allergies, as a result, many patients prefer hospital pharmacies over retail pharmacies.

North America peanut allergy treatment market accounted for 41.3% of market share in global market in 2023 and is predicted to reach USD 531.6 million by 2032.
 

• The leading share of North America can be attributed to increasing prevalence of peanut allergies in the region. According to a September 2021 study published in the National Center for Biotechnology Information, the prevalence of peanut allergies increased by about 3.5 times since 1997, reaching 1.5-2% in the U.S. Owing to an increasing prevalence of peanut allergies, the demand for its treatment has surged in the region.
   
• Moreover, increasing approval of immunotherapies is also contributing to the revenue growth in the market in North America. For instance, in February 2024, US FDA approved Xolair injection, an oral immunotherapy product for patients aged 4 to 17 years.
   

The U.S. peanut allergy treatment market was valued at USD 174.1 million in 2023 and is anticipated to grow at a CAGR of 11.7% over the forecast period.
 

• Increasing awareness for peanut allergies in the U.S. through awareness campaigns has surged the number of parents opting for early peanut exposure to their infants for timely diagnosing peanut allergies. According to the National Peanut Board, since 2001, Farmers in the U.S. have invested more than USD 36 million to help solve the peanut allergy issues through educational and research outreach.
   
• Furthermore, increasing investments in the country for developing new therapeutic candidates to effectively treating allergies is also contributing to an increasing availability of approved treatments options in the country. For instance, in July 2021, Vedanta Biosciences, Inc. received USD 68 million series D financing for various pipeline candidates including VE416 for treating peanut allergy. Such investments are driving the research and developments activities in the country.
   

Germany peanut allergy treatment market is expected to show lucrative growth opportunities during the forecast period.
 

• Growing awareness for peanut allergies in the Germany due to high incidence of fatal food allergies is driving the demand for its timely treatment. According to an October 2023 article from American Association of Allergy, Asthma & Immunology, Germany reported a total of about 305 fatal allergic reactions among children and adults due to drugs, insects, and food. As a result, the parents in Germany are increasingly opting for timely diagnosis of allergies, thereby increasing the demand for its timely treatment.
   
• Furthermore, presence of advanced pharmaceutical research and development and manufacturing facilities in Germany is attracting vendors to increasingly collaborate with the local contract manufacturing organizations and contract research organizations to boost their pipeline production for use in clinical studies. For instance, Allergy therapeutics plc announced its collaboration with Germany based AGC Biologics for scaling up Polyvac peanut product to be used in clinical studies.
   

Australia peanut allergy treatment market is anticipated to show remarkable growth over the coming years.
 

• High incidence of peanut allergies among patients aged one year is driving the demand for treating peanut allergies. According to the Allergy and Anaphylaxis Australia, about 3% of children of age one year suffer from peanut allergies. However, owing to significant awareness among parents, about 20% of children grow out of their peanut allergies. Increased awareness in the Australia together with high incidence of peanut allergy is contributing to its increasing growth in the market.
   
• Additionally, growing support from government in pharmaceutical research for developing novel therapeutic candidate for peanut allergies is also contributing to the growth of market in Australia. In January 2023, Government of Australia invested about USD 12 million in Avarax, a company involved in developing breakthrough immunotherapeutic treatment for peanut allergy. Growth in funding for peanut allergy therapies from government and private organizations in Australia is expected to offer lucrative growth opportunities to the vendors during the forecast period.
   

Peanut Allergy Treatment Market Share

The market for peanut allergy treatment is concentrated due to the requirement of high initial capital investments for developing therapeutic candidate. Moreover, uncertainty towards the success of therapy during clinical trials exposes smaller vendors to a high risk of financial losses, limiting their entry into the market. On the other hand, established vendors have significant expertise and financial resources to develop and commercialize new therapeutic candidates.
 

The market is witnessing a limited availability of approved and commercialized immunotherapy products that are indicated for treating peanut allergy. The vendors have significant number of products currently in pipeline stage, and the competition is more focused towards gaining an early entry into the market.
 

Peanut Allergy Treatment Market Companies

Prominent players operating in the peanut allergy treatment industry include:

• Adamis Pharmaceuticals Corporation
• AdvaCare Pharma
• Aimmune Therapeutics Inc.
• Amneal Pharmaceuticals LLC
• Amphastar Pharmaceuticals, Inc.
• CVS Pharmacy
• DBV Technologies
• Grand Pharma (China) Co., Ltd. 
• Kaleo
• Mylan N.V.
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Sanofi
• TerSera Therapeutics LLC 
• Teva Pharmaceuticals Industries Ltd.
   

Peanut Allergy Treatment Industry News:

• In February 2024, Novartis announced the U.S. FDA approval of Xolair (omalizumab), a first treatment for paediatric patients and adults with one or more food allergies including anaphylaxis.
   
• In November 2023, Aimmune Therapeutics, Inc. announced the U.S. FDA approval of PALFORZIA for use in patients of age 4-17 with peanut allergy. PALFORZIA is indicated for use in combination with a peanut-avoidant diet.
   

The peanut allergy treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Route of Administration

• Injectable
• Oral
• Other routes of administration

Market, By Drug Class

• Epinephrine
• Antihistamines
• Immunotherapies
• Other drug classes

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa